• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    BioCryst Pharmaceuticals (BCRX) Could Be 54% Undervalued Following Strong Earnings Guidance

    Simply Wall St·08/11/2026 16:26:46
    Listen to the news

    BioCryst Pharmaceuticals (BCRX) is back in focus after its second quarter 2026 report, which combined higher revenue, a sharp improvement in quarterly net income and a raised full year revenue outlook.

    See our latest analysis for BioCryst Pharmaceuticals.

    That earnings update landed alongside a sharp shift in sentiment around BioCryst Pharmaceuticals, with the stock posting a 4.90% 1 day share price return and an 11.69% 7 day share price return. The 1 year total shareholder return of 20.00% sits against a 5 year total shareholder return that is still down 35.56%, suggesting recent momentum is improving but the longer term record remains mixed.

    If BioCryst Pharmaceuticals has you looking at healthcare and biotech differently, it could be a good moment to broaden your watchlist through the Simply Wall St screener for 43 healthcare AI stocks

    Given BioCryst Pharmaceuticals now shows stronger quarterly earnings alongside a sizable rebound in the share price, it matters whether this move reflects the underlying business or a swing in sentiment, which brings the valuation into focus next.

    Most Popular Narrative: 53.8% Undervalued

    The most followed narrative values BioCryst Pharmaceuticals at $21.30 per share against a last close of $9.84, which is a wide gap that comes down to a specific set of growth and profitability assumptions.

    Strong and sustainable revenue growth for ORLADEYO, supported by increasing new patient prescriptions, expanding prescriber base, and robust retention rates, positions BioCryst to capitalize on the rising prevalence and earlier diagnosis of rare diseases, likely driving sustained top-line expansion and improved profit margins.

    Read the complete narrative. Read the complete narrative.

    Want to see what turns current losses into the earnings profile behind that fair value? The narrative leans on shifting margins, measured revenue growth and a richer future earnings multiple that stands well above typical biotech levels.

    Result: Fair Value of $21.30 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this BioCryst Pharmaceuticals narrative still hinges on heavy reliance on ORLADEYO and the uncertain progress of early stage programs like Netherton syndrome and DME.

    Find out about the key risks to this BioCryst Pharmaceuticals narrative.

    Next Steps

    Mixed views on whether BioCryst Pharmaceuticals is on the right track after this update. Use the full risk and reward breakdown to test that instinct and shape your own conclusion with 3 key rewards and 2 important warning signs

    Looking for more BioCryst Pharmaceuticals sized opportunities?

    If BioCryst Pharmaceuticals has sharpened your interest in what else is out there, do not stop here. Use fresh ideas from curated stock lists to keep building your edge.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.